Advice

In the absence of a submission from the holder of the marketing authorisation

bosentan (Tracleer) is not recommended for use within NHSScotland to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice50KB (PDF)

Download

Medicine details

Medicine name:
bosentan 62.5mg 125mg film coated tablets (Tracleer)
SMC ID:
485/08
Indication:
to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease
Pharmaceutical company
Actelion Pharmaceuticals UK Ltd
BNF chapter
Cardiovascular system
Submission type
Non submission
Status
Not recommended
Date advice published:
09 June 2008